Page 298 - Read Online

Page 14 of 16 Lei et al. J Cancer Metastasis Treat 2019;5:38 I http://dx.doi.org/10.20517/2394-4722.2019.12

regulated sites and examination of their influence on transcriptional activity. J Biol Chem 1994;269:4458-66.
4. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, et al. Activation of the estrogen receptor through phosphorylation by mitogen-
activated protein kinase. Science 1995;270:1491-4.
5. Zhou W SJ. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer
2014;14:26-38.
6. Zwart W, de Leeuw R, Rondaij M, Neefjes J, Mancini MA, et al. The hinge region of the human estrogen receptor determines functional
synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J Cell Sci 2010;123:1253-61.
7. Early Breast Cancer Trialists' Collaborative G (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, et al. Relevance of breast cancer
hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet
2011;378:771-84.
8. Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 2015;15:261-75.
9. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and
HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
10. Arpino G, Green SJ, Allred DC, Lew D, Martino S, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen
receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670-6.
11. Fan P, Wang J, Santen RJ, Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the
nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 2007;67:1352-60.
12. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, et al. The role of Shc and insulin-like growth factor 1 receptor in mediating the
translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 2004;101:2076-81.
13. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone
receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011;17:1147-59.
14. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013;3:27-34.
15. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase
inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011;13:R21.
16. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al. Everolimus in postmenopausal hormone-receptor-positive advanced
breast cancer. N Engl J Med 2012;366:520-9.
17. Di Leo A, Johnston S, Lee KS, Ciruelos E, Lonning PE, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-
receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:87-100.
18. André F, Ciruelos EM, Rubovszky G, Campone M, Loibl S, et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC):
results of the phase 3 SOLAR-1 trial. Munich, Germany: ESMO Congress; 2018.
19. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
20. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, et al. Therapeutically activating RB: reestablishing cell cycle control in
endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011;18:333-45.
21. Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and
anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res 2017;23:4055-65.
22. Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, et al. Frequent ESR1 and CDK pathway copy-number alterations in
metastatic breast cancer. Mol Cancer Res 2019;17:457-68.
23. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a
metastatic breast cancer. Cancer Res 1997;57:1244-9.
24. Pejerrey SM, Dustin D, Kim JA, Gu G, Rechoum Y, et al. The impact of ESR1 mutations on the treatment of metastatic breast cancer.
Horm Cancer 2018;9:215-28.
25. Niu J, Andres G, Kramer K, Kundranda MN, Alvarez RH, et al. Incidence and clinical significance of ESR1 mutations in heavily
pretreated metastatic breast cancer patients. Onco Targets Ther 2015;8:3323-8.
26. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, et al. HER-2/neu amplification predicts poor survival in node-positive breast
cancer. Cancer Res 1990;50:4332-7.
27. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic
target in breast cancer. Cancer Res 2010;70:2085-94.
28. Nembrot M, Quintana B, Mordoh J. Estrogen receptor gene amplification is found in some estrogen receptor-positive human breast
tumors. Biochem Biophys Res Commun 1990;166:601-7.
29. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
Nat Genet 2007;39:655-60.
30. Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet
2008;40:806-7.
31. Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, et al. ESR1 gene amplification in breast cancer: a common phenomenon?
Nat Genet 2008;40:807-8.
32. Reis-Filho JS, Drury S, Lambros MB, Marchio C, Johnson N, et al. ESR1 gene amplification in breast cancer: a common phenomenon?
Nat Genet 2008;40:809-10.
33. Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O. ESR1 gene amplification in breast cancer: a common phenomenon? Nat
Genet 2008;40:809.
34. Tsiambas E, Georgiannos SN, Salemis N, Alexopoulou D, Lambropoulou S, et al. Significance of estrogen receptor 1 (ESR-1) gene
imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis. Med Oncol 2011;28:934-40.
35. Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, et al. Estrogen receptor alpha gene ESR1 amplification may predict endocrine